Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Ono to pay Biohaven $80M for protein degrader; UK pulls Valneva's chikungunya vaccine

8 October 2026 · By · Wire by Fusion42

Published

8 October 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United Kingdom

◆ Source

Read at endpoints.news →

◆ Verified

Fusion42 · 10 October 2026 · Fusion42 review

Ono Pharmaceutical has agreed to pay Biohaven $80 million for rights to a protein degrader drug in Japan and select Asian regions, while the UK has withdrawn Valneva's chikungunya vaccine from the market.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face new regulatory uncertainty in the UK vaccine market that could disrupt go-to-market plans, while Biohaven's partnership with Ono opens fresh regional licensing avenues in Asia—pivot your market entry strategies accordingly.

◆ Coverage

1 source · 8 Oct 2026

◆ Related on Wire

◆ Topics

Biotechbiohavenono-pharmaprotein-degradervalnevavaccine-withdrawaluk-regulation